Effect of the alpha-glucosidase-inhibitor BAY-g-5421 on blood glucose control of sulphonylurea-treated diabetics and insulin-treated diabetics.
D000328:Adult; D000368:Aged; D001786:Blood Glucose / Q000378:metabolism*; D002986:Clinical Trials as Topic; D003511:Cyclohexanols; D003920:Diabetes Mellitus / Q000097:blood* / Q000188:drug therapy; D005260:Female; D005959:Glucosidases / Q000037:antagonists & inhibitors*; D065089:Glycoside Hydrolase Inhibitors; D006801:Humans; D007328:Insulin / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009844:Oligosaccharides; D013453:Sulfonylurea Compounds / Q000627:therapeutic use*; D014312:Trisaccharides
D001786:Blood Glucose; D003511:Cyclohexanols; D065089:Glycoside Hydrolase Inhibitors; D007328:Insulin; D009844:Oligosaccharides; D013453:Sulfonylurea Compounds; D014312:Trisaccharides; D005959:Glucosidases